Fabtech Technologies Quarterly Results for Trading Insights
In Mar 2026, Fabtech Technologies (FABTECH) reported revenue ₹168 Cr and net profit ₹22 Cr — revenue +21.7% YoY. For annual financials, live price and key ratios, visit Fabtech Technologies share price screener.
FABTECH Quarterly Results — Revenue, Profit & EPS Highlights
Fabtech Technologies latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. Also explore FABTECH share price charts to track price trends across different timeframes.
- Revenue of ₹168 Cr in Mar 2026 (+34.4% vs Sept 2025, +21.7% vs Mar 2025)
- Net Profit of ₹22 Cr in Mar 2026 (-21.4% vs Sept 2025, +46.7% vs Mar 2025)
- EBITDA of ₹32 Cr in Mar 2026 (-5.9% vs Sept 2025)
- Operating Margin of 14.0% in Mar 2026 (-11.0pp vs Sept 2025)
- Earnings Per Share of ₹5.75 in Mar 2026 (-33.8% vs Sept 2025)
Fabtech Technologies Quarterly Results — Revenue, EBITDA, Net Profit & EPS
FABTECH quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Mar 2026 | Sept 2025 | Mar 2025 | Jun 2025 | Dec 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 168 | 125 | 138 | 71 | 70 | 34.4% | 21.7% |
| Net Profit (₹ Cr) | 22 | 28 | 15 | -6 | -6 | - | - |
| EBITDA (₹ Cr) | 32 | 34 | 22 | -4 | -5 | - | - |
| EPS (₹) | 5.75 | 8.68 | 4.66 | -1.89 | -1.56 | - | - |
| Operating Margin (%) | 14.0% | 25.0% | 14.0% | -9.0% | -18.0% | - | - |
FABTECH Share Price Trend — 1-Year Movement Across Quarterly Results
Fabtech Technologies 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Compare with FABTECH stock valuation models to assess whether the stock is under or overvalued.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
FABTECH vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Fabtech Technologies latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2025 |
₹450,643.09 Cr | 1891.3 | 14,875 | 3,125 | +10.8% | - | 21.0% | 145.5 |
|
Divis Laboratories
Sept 2025 |
₹179,470.03 Cr | 6858.0 | 2,860 | 689 | +7.1% | - | 24.1% | 264.1 |
|
Torrent Pharmaceuti…
Sept 2025 |
₹148,702.77 Cr | 4469.2 | 3,219 | 591 | +11.3% | - | 18.4% | 254.8 |
|
Cipla
Mar 2026 |
₹115,205.68 Cr | 1401.9 | 6,612 | 543 | -14.3% | -4.0% | 8.2% | 204.1 |
|
Dr Reddys Laborator…
Mar 2026 |
₹111,107.68 Cr | 1318.5 | 7,996 | 221 | -12.5% | -11.5% | 2.8% | 497.5 |
All amounts in ₹ Crores